ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2429

Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus

Vincent A. Laufer1, Maria I. Danila2, Richard J. Reynolds3, Leah C. Kottyan4, Kenneth Kaufman5, John B. Harley6, Carl D Langefeld7, Donna Arnett8 and S. Louis Bridges Jr.9, 1Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 6Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Wake Forest University, Winston Salem, NC, 8University of Kentucky College of Public Health, Lexington, KY, 9Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Functional Genomics, Genetic architecture, meta-analysis and rheumatoid arthritis (RA), Personalized Medicine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Genetic variants in AFF3 have been associated with RA, including in our GWAS and ImmunoChip analyses of African-Americans (610 RA; 1543 controls). Likewise, an AFF3 SNP (rs10865035) has been associated with response of RA to TNF inhibitors (TNFi) (Ann Rheum Dis. 2010 69:1029). AFF3 encodes LAF4, a tissue-restricted nuclear transcriptional activator expressed in cells such as monocytes and lymphocytes. Variants most strongly associated with RA are in the 5′ UTR; several are expression quantitative trait loci (eQTLs) for AFF3. We examined trans-ethnic associations of AFF3 with RA, prioritized candidate pathogenic variants using established algorithms, and compared this list to variants reported to influence the likelihood of response to TNFi in RA. 

Methods: We aggregated our African American RA genetic data with publicly available GWAS data from >100,000 European and Asian RA patients and controls, using METASOFT meta-analysis software to assess overall trans-ethnic association strength (pTE) and concordance of effects in each ethnicity (m-value).  m>0.8 indicates high likelihood of existence of effect for a given population. We then used the PAINTOR3 algorithm (which incorporates multiple types of data) on data from all 3 ancestries to prioritize SNPs according to likelihood of being pathogenic. We compared this list to variants implicated in TNFi response. 

Results: We found strong evidence (m>0.9) of trans-ethnic effect on RA for 91 AFF3 variants, mostly in the 5′ UTR. We confirmed the association of the AFF3 locus and the previously reported index variant (rs9653442) with RA in African-Americans (pAFR = 7.4*10-3, mAFR = 0.975). rs9653442 has a robust trans-ethnic association with RA (mEUR = 1.000; mASIAN = 0.999; mAFR = 0.975; pTE = 1.14*10-15). We identified a set of 12 variants that together are >90% likely to include the pathogenic variant (the 90% ancestry informed credible set, see Table). rs10865035, which was previously associated with TNFi response in RA, was outside our 90% ancestry informed credible set.

Conclusion: We defined a set of 12 leading candidate pathogenic AFF3 variants, which may act to increase AFF3 expression in T cells or monocytes and influence RA susceptibility. Our study did not identify a likely pathogenic role for rs10865035 in RA susceptibility, but further studies are needed to establish whether rs10865035 underlies differences in TNFi response in RA. Our findings will guide selection of SNPs for future functional studies of susceptibility to RA. 


Description: Macintosh HD:Users:vincentlaufer:Desktop:Table_ACR.jpg

Table – The 90% ancestry informed credible set for pathogenic AFF3 variants in RA and their characteristics. eQTL data are from the NESDA NTR Conditional eQTL Catalog (peripheral blood was used). Z.Afr, Z.Asn, Z.Eur are Z-statistics for each variant from each GWAS.  Abbreviations: Alt – Alternate.  CS – Chromatin State. HS – DNAse hypersensitive region. TFBS – transcription factor binding site.


Disclosure: V. A. Laufer, None; M. I. Danila, None; R. J. Reynolds, None; L. C. Kottyan, None; K. Kaufman, None; J. B. Harley, None; C. D. Langefeld, None; D. Arnett, None; S. L. Bridges Jr., None.

To cite this abstract in AMA style:

Laufer VA, Danila MI, Reynolds RJ, Kottyan LC, Kaufman K, Harley JB, Langefeld CD, Arnett D, Bridges SL Jr.. Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/towards-precision-medicine-in-rheumatoid-arthritis-ra-trans-ethnic-analysis-and-prioritization-of-snps-in-the-aff3-locus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/towards-precision-medicine-in-rheumatoid-arthritis-ra-trans-ethnic-analysis-and-prioritization-of-snps-in-the-aff3-locus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology